4//SEC Filing
Reddoch James F. 4
Accession 0000950103-21-008570
CIK 0001802768other
Filed
Jun 7, 8:00 PM ET
Accepted
Jun 8, 8:12 PM ET
Size
12.5 KB
Accession
0000950103-21-008570
Insider Transaction Report
Form 4
Reddoch James F.
EVP, Research & Investments
Transactions
- Sale
Class A Ordinary Shares
2021-06-07$46.57/sh−47,790$2,225,523→ 1,323,010 total(indirect: By LLC) - Sale
Class A Ordinary Shares
2021-06-04$44.60/sh−100,000$4,459,730→ 1,370,800 total(indirect: By LLC) - Sale
Class A Ordinary Shares
2021-06-08$46.43/sh−50,000$2,321,540→ 1,270,800 total(indirect: By LLC) - Sale
Class A Ordinary Shares
2021-06-07$47.01/sh−2,210$103,896→ 1,320,800 total(indirect: By LLC)
Holdings
- 25,030(indirect: By IRA)
Class A Ordinary Shares
Footnotes (4)
- [F1]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.14 to $45.06 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.99 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Such transactions were effected pursuant to a 10b5-1 plan adopted by the reporting person on December 30, 2020.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.02 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Such transactions were effected pursuant to a 10b5-1 plan adopted by the reporting person on December 30, 2020.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.30 to $46.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Royalty Pharma plc
CIK 0001802768
Entity typeother
Related Parties
1- filerCIK 0001814872
Filing Metadata
- Form type
- 4
- Filed
- Jun 7, 8:00 PM ET
- Accepted
- Jun 8, 8:12 PM ET
- Size
- 12.5 KB